# Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery

> **NCT00305825** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 43 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** letrozole

## Key facts

- **NCT ID:** NCT00305825
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2006-05-30
- **Final completion:** 2016-05-24
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2017-08-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00305825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00305825, "Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00305825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*